home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410m.zip
/
M94A2374.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
40 lines
Document 2374
DOCN M94A2374
TI Disease progression and survival among HIV-infected injecting drug users
(IDUs) by gender.
DT 9412
AU Brown L; Neaton JD; Wentworth DN; Sherer R; Besch L; Addiction Research
& Treatment Corp., Brooklyn, NY 11201.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):319 (abstract no. PC0207). Unique
Identifier : AIDSLINE ICA10/94370201
AB OBJECTIVE: To compare HIV disease progression and mortality according to
gender among HIV-infected injecting drug users (IDU). METHOD: IDUs (370
females and 999 males) receiving HIV-related primary care at Clinical
Centers (CC) participating in the Community Programs for Clinical
Research on AIDS provided demographic and HIV-related clinical
information at intervals of 6 months or less. Using a proportional
hazards model, we calculated relative risks (RR) stratified by CC with
covariates of CD4 count, age, race, Karnofsky score, disease progression
(DP) history, and use of anti-retroviral (AR) drugs and PCP prophylaxis.
RESULTS: At study entry, compared to male IDUs, females were more likely
to be Black (58% vs. 47%), had a higher mean baseline CD4 (319 vs. 240
cells/cu mm), were less likely to report a prior opportunistic disorder
(23% vs. 30%), and were less likely to be prescribed AR therapy (56% vs.
63%) or PCP prophylaxis (37% vs. 53%). Through 9/93, there were 93 DP
events and 57 deaths among the women compared to 306 and 166,
respectively, for men. The adjusted RR (women/men) for disease
progression was 0.95 (95% CI: 0.73-1.22) and for death 1.68 (95% CI:
1.2-2.35, p < .01). CONCLUSION: These data suggest a greater risk for
death for women compared to men among IDUs, despite lesser degrees of
immunosuppression.
DE Antiviral Agents/THERAPEUTIC USE AIDS-Related Opportunistic
Infections/PREVENTION & CONTROL Blacks Female Human HIV
Infections/COMPLICATIONS/DRUG THERAPY/*MORTALITY Male Pneumonia,
Pneumocystis carinii/PREVENTION & CONTROL Risk Factors Sex Factors
Substance Abuse, Intravenous/*COMPLICATIONS Support, U.S. Gov't, P.H.S.
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).